Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.1 USD | -0.56% | +8.49% | -35.16% |
04-25 | Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained | MT |
04-25 | Transcript : Sage Therapeutics, Inc., Q1 2024 Earnings Call, Apr 25, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.16% | 853M | |
-3.17% | 102B | |
+1.63% | 96.29B | |
+2.13% | 22.18B | |
-15.80% | 21.2B | |
-9.21% | 18.31B | |
-39.98% | 17.38B | |
-15.04% | 16.36B | |
+5.27% | 13.97B | |
+32.94% | 12.17B |
- Stock Market
- Equities
- SAGE Stock
- News Sage Therapeutics, Inc.
- Sage Therapeutics : Biogen Say Zuranolone Study Meets Primary Endpoint in Patients With Major Depressive Disorder